A. Sosulski

AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer

Cesar M. Castro, P. Donahoe, M. Birrer, 2015, Proceedings of the National Academy of Sciences.

AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy

P. Donahoe, L. Zhang, H. Saatcioglu, 2017, Proceedings of the National Academy of Sciences.

CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis

Cesar M. Castro, K. Lage, P. Donahoe, 2016, PloS one.

Abstract A42: An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant c-terminal Mullerian inhibiting substance

P. Donahoe, D. Vavvas, D. Pépin, 2013 .

An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance.

A. Marmalidou, F. Nicolaou, L. A. Benedict, 2013, Technology.